Company Analysis
Sign in

BioXcel Therapeutics, Inc. (BTAI)

OTC: BTAI · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2017
Full chart Alerts Compare
Grade3.3
◀ Past 2.9● Present 3.1▶ Future 3.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

19 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioXcel Therapeutics, Inc.’s names, not what it holds today.

Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 7 in 2024 and 7 in 2023
Applications published
44
6 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals17
Computer technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
BioXcel Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
33 published
BioXcel Therapeutics, Inc. its own name
US, as the owner printed on each patent
17 granted
8 published
OnkosXcel Therapeutics, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
OnkosXcel Therapeutics, LLC a subsidiary
US, as the owner printed on each patent
2 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 22, 202512,364,683Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Nov 12, 202412,138,247Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Oct 8, 202412,109,196Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Sep 17, 202412,090,140Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Jun 4, 202411,998,529Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Jun 4, 202411,998,528Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Mar 19, 202411,931,340Use of sublingual dexmedetomidine for the treatment of agitationPharmaceuticalsBioXcel Therapeutics, Inc.
Feb 6, 202411,890,272Non-sedating dexmedetomidine treatment regimensPharmaceuticalsBioXcel Therapeutics, Inc.
Dec 12, 202311,839,604Use of sublingual dexmedetomidine for the treatment of agitationPharmaceuticalsBioXcel Therapeutics, Inc.
Nov 7, 202311,806,429Film formulations containing dexmedetomidine and methods of producing themPharmaceuticalsBioXcel Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325521USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATIONPharmaceuticalsBioXcel Therapeutics, Inc.
Oct 16, 20252025/0319069METHODS FOR TREATING DEPRESSIVE STATESPharmaceuticalsBioXcel Therapeutics, Inc.
Oct 2, 20252025/0302808DEXMEDETOMIDINE TREATMENT REGIMENSPharmaceuticalsBioXcel Therapeutics, Inc.
Jul 17, 20252025/0228833METHODS AND COMPOSITIONS FOR TREATING AGITATIONPharmaceuticalsBioXcel Therapeutics, Inc.
Jul 3, 20252025/0213681NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATIONPharmaceuticalsOnkosXcel Therapeutics, LLC
Mar 27, 20252025/0099430PREVENTION OR TREATMENT OF SLEEP DISORDERS USING DEXMEDETOMIDINE FORMULATIONPharmaceuticalsBioXcel Therapeutics, Inc.
Aug 22, 20242024/0277669NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSPharmaceuticalsBioXcel Therapeutics, Inc. · patent 12,364,683 granted from it
Aug 1, 20242024/0252471NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSPharmaceuticalsBioXcel Therapeutics, Inc. · patent 12,090,140 granted from it
Aug 1, 20242024/0252470USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATIONPharmaceuticalsBioXcel Therapeutics, Inc.
Jul 25, 20242024/0245651NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSPharmaceuticalsBioXcel Therapeutics, Inc. · patent 12,138,247 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 17.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BTAI · research, not advice